These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9108806)

  • 1. Drug patent expirations and the speed of generic entry.
    Bae JP
    Health Serv Res; 1997 Apr; 32(1):87-101. PubMed ID: 9108806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entry decisions in the generic pharmaceutical industry.
    Morton FM
    Rand J Econ; 1999; 30(3):421-40. PubMed ID: 10558596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of being first: evidence from Canadian generic pharmaceuticals.
    Hollis A
    Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
    Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
    Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are we living in the end of the blockbuster drug era?
    Debnath B; Al-Mawsawi LQ; Neamati N
    Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent trends in brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R
    J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evergreening, patent challenges, and effective market life in pharmaceuticals.
    Hemphill CS; Sampat BN
    J Health Econ; 2012 Mar; 31(2):327-39. PubMed ID: 22425766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovation strategies for generic drug companies: moving into supergenerics.
    Ross MS
    IDrugs; 2010 Apr; 13(4):243-7. PubMed ID: 20373253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rise of the generic drug market and its implications for dermatology.
    Bhosle M; Balkrishnan R; Dewan T; Yelverton CB; Feldman SR
    J Dermatolog Treat; 2005; 16(5-6):295-8. PubMed ID: 16428148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teva v. Eisai: what's the real "controversy"?
    Wang GL
    Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five drugs facing key patent expirations and potential generic entry from April to May 2020.
    Friedman Y
    Pharm Pat Anal; 2020 May; 9(2):41-43. PubMed ID: 32314664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.